US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARYA Sciences Acquisition Corp II

10.10

0.0000

Volume:- -

Turnover:- -

Market Cap:193.78M

PE:- -

High:10.10

Open:10.10

Low:10.10

Close:10.10

52wk High:13.94

52wk Low:9.90

Shares:19.19M

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease

Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARYB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ARYB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARYB\",,,,,undefined,":{"symbol":"ARYB","market":"US","secType":"STK","nameCN":"ARYA Sciences Acquisition Corp II","latestPrice":10.1,"timestamp":1603828800000,"preClose":10.1,"halted":8,"volume":0,"delay":0,"floatShares":0,"shares":19186500,"eps":0,"marketStatus":"Post-Mkt","change":0,"latestTime":"08-18 16:27:07 EDT","open":10.1,"high":10.1,"low":10.1,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1755561600000},"marketStatusCode":4,"symbolChange":{"newSymbol":"CERE","executeDate":"2020-10-28"},"adr":0,"exchange":"NASDAQ","adjPreClose":10.1,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARYB\",,,,,undefined,":{"symbol":"ARYB","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":19186500,"dividePrice":0,"high":10.1,"amplitude":0,"preClose":10.1,"low":10.1,"week52Low":9.9,"pbRate":"--","week52High":13.94,"institutionHeld":0,"latestPrice":10.1,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":10.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARYB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-10-28","symbol":"ARYB","oldSymbol":"ARYB","defaultRemindTime":1603891800000,"newSymbol":"CERE","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1603857600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARYB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARYB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARYB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2140993334","title":"ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details","url":"https://stock-news.laohu8.com/highlight/detail?id=2140993334","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2140993334?lang=en_us&edition=fundamental","pubTime":"2021-06-02 05:02","pubTimestamp":1622581320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=18505200","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["ARYA","ARYB","BGC"],"gpt_icon":0},{"id":"2079620850","title":"Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2079620850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2079620850?lang=en_us&edition=fundamental","pubTime":"2020-10-30 19:00","pubTimestamp":1604055600,"startTime":"0","endTime":"0","summary":"Company developing investigational treatment for both newly diagnosed patients and those with a more advanced form of the disease in need of adjunctive therapy. “We are encouraged by the benefit-risk profile of tavapadon based on the efficacy results observed in Phase 2 trials, as well as the tolerability profile we have seen in our clinical program to date,” said Raymond Sanchez, M.D., chief medical officer of Cerevel Therapeutics. “We look forward to advancing the development of tavapadon and ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fW3L52nQOWxaELXYKPqjag--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Ye6Kp76DNhK0VYj3OG9vXw--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0328382de8ced6d60e6da0fbc1903d50","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fW3L52nQOWxaELXYKPqjag--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Ye6Kp76DNhK0VYj3OG9vXw--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0328382de8ced6d60e6da0fbc1903d50"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cerevel-therapeutics-announces-first-patients-110000700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARYBU","CERE","CEREW","ARYB"],"gpt_icon":0},{"id":"2078579216","title":"Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2078579216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2078579216?lang=en_us&edition=fundamental","pubTime":"2020-10-28 19:00","pubTimestamp":1603882800,"startTime":"0","endTime":"0","summary":"Business combination transaction with Arya Sciences Acquisition Corp II, a special purpose acquisition company sponsored by Perceptive Advisors, completed on October 27, 2020. Cerevel Therapeutics common stock and warrants commence trading today on the Nasdaq Capital Markets under ticker symbols “CERE” and “CEREW” respectively. Net proceeds from this transaction totaled approximately $440 million, combining funds held in Arya II’s trust account and a concurrent PIPE financing. About This Transac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fW3L52nQOWxaELXYKPqjag--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Ye6Kp76DNhK0VYj3OG9vXw--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0328382de8ced6d60e6da0fbc1903d50","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fW3L52nQOWxaELXYKPqjag--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Ye6Kp76DNhK0VYj3OG9vXw--~B/aD0yMDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0328382de8ced6d60e6da0fbc1903d50"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cerevel-therapeutics-debuts-publicly-traded-110000392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARYBU","ARYB"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ARYB\",params:#limit:6,delay:false,,,undefined,":[]}}